INCB007839

DRUG2 trials

Sponsors

Incyte Corporation

Conditions

Breast CancerSolid Tumors and Hematologic Malignancy

Phase 1

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

CompletedNCT00820560

Incyte CorporationSolid Tumors and Hematologic Malignancy

Start: 2005-01-31End: 2009-01-31Updated: 2018-01-17

Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

TerminatedNCT00864175

Incyte CorporationBreast Cancer

Start: 2007-07-31End: 2011-10-31Updated: 2018-01-18